CORONA Remedies Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Tue Apr 14 2026

CORONA Remedies (NSE: CORONAREME) is scheduled to declare its Q4 FY26 results on May 15, 2026, when the board of directors will approve the audited financial statements for the January–March 2026 quarter and the full year FY2025–26. The stock trades at Rs 680 as of April 2026 — down -35% from its 52-week high of Rs 1,050 — making this a closely watched quarter for investors assessing whether the correction represents opportunity or ongoing fundamental pressure.

This Q4 FY26 results preview for CORONA Remedies covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook. Q4 FY26 is particularly significant as it delivers the full-year FY26 results alongside the first management commentary on FY27 business outlook.

Get free investment predictions from SEBI-registered analysts on Univest.

Table of Contents

CORONA Remedies Q4 Results 2026 Date

The CORONA Remedies Q4 FY26 results date is May 15, 2026. The board of directors meeting will approve the quarter and full-year FY26 financial results, consider a final dividend recommendation for FY26, and provide management guidance for FY27.

Company	Q4 Results Date	Key Metric to Watch
[object Object]	April 9, 2026 (Declared)	FY27 CC guidance + deal TCV
[object Object]	April 23, 2026	CC revenue growth guidance
Bharti Airtel	April 29, 2026	ARPU + 5G subscribers
Dr. Lal Path Labs	May 8, 2026	Test volume + EBITDA margin
CORONA Remedies	May 15, 2026	See estimates below

Why Q4 FY26 Matters

Q4 (January–March 2026) is the final quarter of FY2025–26 and carries the highest informational weight of any quarterly result. Beyond the Q4 standalone performance, investors receive: the complete FY26 annual revenue, PAT, and margin profile; management’s first formal FY27 revenue and margin guidance; the final dividend recommendation; and qualitative commentary on demand environment and competitive dynamics entering the new fiscal year.

For CORONA Remedies specifically, Q4 captures the peak-season dynamics of the Pharma / Generic sector — a quarter where operating leverage typically manifests most visibly if demand conditions are favourable.

CORONA Remedies Q4 FY26 Earnings Estimates

CORONA Remedies Q4 FY26 analyst consensus estimates — Revenue, PAT, Margin | univest.in

Access premium analyst research on Univest.

Based on publicly available analyst consensus data, the following are the Q4 FY26 estimates for CORONA Remedies:

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	QoQ Trend
Revenue	Rs 285 Cr	Rs 255 Cr	Sequential improvement expected
Net Profit (PAT)	Rs 22 Cr	Rs 19 Cr	Normalisation in progress
Margin	EBITDA 12%	Q3 FY26 level	Stable to improving
Volume / Growth Driver	+12% revenue YoY	Prior quarter	YoY comparison
Final Dividend (Expected)	Rs 1	FY26 interim dividends	Board decision

Screen CORONA Remedies live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.

Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving CORONA Remedies Q4 FY26 Performance

1. India Branded Generic Growth

India pharmaceutical market (IPM) growing at 8–10% annually. Q4 captures year-end prescription momentum and seasonal demand for respiratory and anti-infective products.

2. Export Market Development

Regulated market (US, EU) and emerging market (Africa, CIS) export revenue diversifies beyond the domestic market and typically carries higher margins.

3. New Product Launches

ANDA approvals, new molecule registrations, and brand extensions expand the addressable market within existing therapeutic areas.

4. Field Force Productivity

Medical representative (MR) productivity and coverage quality determine prescription generation. Management commentary on field force efficiency is a key quality indicator.

5. Raw Material API Costs

API (Active Pharmaceutical Ingredient) procurement costs, which depend on Chinese API pricing and domestic manufacturing capacity, determine gross margin trajectory.

5 Risks to Watch in CORONA Remedies Q4 FY26

Risk 1: Input Cost Volatility

Raw material and input cost changes can compress margins unexpectedly within a quarter.

Risk 2: Revenue Concentration Risk

Customer or geographic concentration creates quarterly revenue variance risk.

Risk 3: Competitive Pressure

Market competition in the Pharma / Generic sector may intensify, requiring additional price or volume concessions.

Risk 4: Regulatory Environment

Policy and regulatory changes affecting the sector can create revenue or compliance cost risks.

Risk 5: Macroeconomic Sensitivity

Global and domestic macroeconomic conditions — tariffs, interest rates, consumption trends — affect end-market demand.

CORONA Remedies Share Price and Analyst Ratings

CORONA Remedies share price and analyst ratings — Q4 FY26 preview | univest.in

Parameter	Value
CMP (April 2026)	Rs 680
52-Week High	Rs 1,050
52-Week Low	Rs 590
1-Year Return	-35%
Market Capitalisation	Rs 1,800 Cr
Sector	Pharma / Generic
NSE Ticker	CORONAREME
Q4 Results Date	May 15, 2026

Brokerage	Rating	Thesis Summary
Motilal Oswal	BUY	Q4 recovery potential; sector tailwinds intact
YES Securities	ADD	Earnings inflection expected; watch Q4 guidance
Kotak Institutional	NEUTRAL	Fair valued at current levels; execution key

Conclusion

CORONA Remedies Q4 FY26 results on May 15, 2026 will be the most important quarterly event of FY26. At Rs 680 — down -35% from its 52-week high of Rs 1,050 — the stock enters results season having already priced in significant headwinds. Revenue above Rs 285 Cr with EBITDA 12% would constitute a beat relative to current analyst consensus. Management’s FY27 guidance on 12% revenue YoY trajectory will be the primary re-rating catalyst.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is CORONA Remedies Q4 results 2026 date?

CORONA Remedies Q4 FY26 results date is May 15, 2026. The board will approve the quarter and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.

Q: What is CORONA Remedies Q4 FY26 revenue estimate?

Analyst consensus estimate for CORONA Remedies Q4 FY26 revenue is Rs 285 Cr. Q3 FY26 actual revenue was Rs 255 Cr. Actual Q4 results may differ based on operating conditions and management execution.

Q: What is CORONA Remedies Q4 FY26 PAT estimate?

Analyst consensus estimate for CORONA Remedies Q4 FY26 net profit (PAT) is Rs 22 Cr. Q3 FY26 actual PAT was Rs 19 Cr. Estimates are indicative and subject to quarterly variance.

Q: Will CORONA Remedies declare a dividend in Q4 FY26?

CORONA Remedies is expected to declare Rs 1 for FY26, subject to board approval at the May 15, 2026 meeting and subsequent shareholder approval at the AGM. Verify actual dividend announcement before making any investment decision.

Q: What is CORONA Remedies current share price?

CORONA Remedies is trading at Rs 680 as of April 2026 — down -35% from its 52-week high of Rs 1,050. The 52-week low is Rs 590. Track the live price on the Univest Screener.

Q: What were CORONA Remedies Q3 FY26 results?

In Q3 FY26, CORONA Remedies reported revenue of Rs 255 Cr and net profit (PAT) of Rs 19 Cr. Q4 FY26 results on May 15, 2026 will provide the full-year FY26 comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered in detail at univest.in/blogs. Check the earnings calendar table above for other key result dates.

Q: Is CORONA Remedies a good investment ahead of Q4 results?

This article does not constitute investment advice. CORONA Remedies at Rs 680 trades -35% below its 52-week high of Rs 1,050. Analyst consensus estimates suggest Q4 FY26 revenue of Rs 285 Cr and PAT of Rs 22 Cr. Review the factors, risks, and analyst ratings above. Consult a SEBI-registered financial advisor before making any investment decision.